SUMICHEM Sumitomo Chemical India Q4 FY25 results (Jan–Mar 2025) and concall
Sumitomo Chemical India delivered a record-breaking FY25, characterized by strong volume-led growth that successfully offset significant pricing pressures. While Q4 faced temporary headwinds in the export market (specifically LATAM) and shipment timing issues, the company achieved its highest-ever annual margins and PAT. Management is pivoting aggressively toward high-margin patented molecules and has committed to a multi-site Capex plan to support both domestic demand and global supply for its parent company.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q3 FY25 | Q4 FY25 |
|---|---|---|
| Revenue | 642 | 679 |
| EBITDA | 106 | 120 |
| Net profit | 87 | 100 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
